Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Recro Acquires Alkermes Mfg. Site in GA | Contract Pharma

What are you searching for?

Sign in
Breaking News

Recro Acquires Alkermes Mfg. Site in GA

Specializes in DEA controlled substance and sustained release formulations

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Recro Pharma, Inc., a pharmaceutical company developing non-opioid therapeutics for the treatment of acute post-operative pain, has acquired the 97,000 sq.-ft. Gainesville, GA manufacturing facility from Alkermes plc. The site, Recro Gainesville LLC, is a solid dose contract development and manufacturing site that specializes in DEA controlled substance manufacturing and packaging, as well as sustained release formulations.
 
Recro offers a range of pharmaceutical development and manufacturing capabilities to support formulation development, analytical method development, process development, clinical supplies manufacturing, commercial manufacturing, as well as tech transfers, and process improvement services.
 
The Gainesville site was built in 1983 and has produced commercial products for several pharma customers ranging from small to large pharma. Recro has ~200 employees, including more than 170 commercial manufacturing and packaging specialists, as well as scientists supporting formulation development and analytical services.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics